Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 4.61 USD 6.47% Market Closed
Market Cap: 375.2m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Codexis Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
Gross Profit
$49m
CAGR 3-Years
-15%
CAGR 5-Years
-1%
CAGR 10-Years
10%
Thermo Fisher Scientific Inc
NYSE:TMO
Gross Profit
$17.3B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Gross Profit
$12.6B
CAGR 3-Years
-9%
CAGR 5-Years
8%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Gross Profit
$2.2B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Gross Profit
$3.6B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
16%
IQVIA Holdings Inc
NYSE:IQV
Gross Profit
$5.4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
14%
No Stocks Found

Codexis Inc
Glance View

Market Cap
375.1m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.92 USD
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Codexis Inc's Gross Profit?
Gross Profit
49m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's Gross Profit amounts to 49m USD.

What is Codexis Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
10%

Over the last year, the Gross Profit growth was -12%. The average annual Gross Profit growth rates for Codexis Inc have been -15% over the past three years , -1% over the past five years , and 10% over the past ten years .

Back to Top